MAIA Biotechnology Gets FDA Orphan Designation for THIO in Glioblastoma

By Colin Kellaher

MAIA Biotechnology has won a third U.S. Food and Drug Administration granted orphan-drug designation for THIO, the clinical-stage biopharmaceutical company's lead asset.

The Chicago company on Friday said the latest designation covers THIO for the treatment of glioblastoma, the most aggressive type of brain tumor.

The FDA's orphan-drug program gives special status to drugs and biologics for diseases and disorders that affect fewer than 200,000 people in the U.S. and provides for an extended marketing exclusivity period against competition.

The FDA last year granted orphan-drug designation to THIO in hepatocellular carcinoma and small-cell lung cancer.

Write to Colin Kellaher at [e-mail]

(END) Dow Jones Newswires

11-10-23 0730ET